The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.

Erin T. Jenkins, Donald M. Jensen

Research output: Contribution to journalReview article

Abstract

An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.

Original languageEnglish
Pages (from-to)879-891
Number of pages13
JournalInfectious Disease Clinics of North America
Volume26
Issue number4
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Hepacivirus
Antiviral Agents
Ribavirin
Interferons
Hepatitis C
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. / Jenkins, Erin T.; Jensen, Donald M.

In: Infectious Disease Clinics of North America, Vol. 26, No. 4, 12.2012, p. 879-891.

Research output: Contribution to journalReview article

@article{ead7f7342f6649a184f12cbb9b3ca073,
title = "The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.",
abstract = "An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.",
author = "Jenkins, {Erin T.} and Jensen, {Donald M.}",
year = "2012",
month = "12",
doi = "10.1016/j.idc.2012.08.007",
language = "English",
volume = "26",
pages = "879--891",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.

AU - Jenkins, Erin T.

AU - Jensen, Donald M.

PY - 2012/12

Y1 - 2012/12

N2 - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.

AB - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.

UR - http://www.scopus.com/inward/record.url?scp=84876450432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876450432&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2012.08.007

DO - 10.1016/j.idc.2012.08.007

M3 - Review article

VL - 26

SP - 879

EP - 891

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 4

ER -